Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.

Ye XS, Fan L, Van Horn RD, Nakai R, Ohta Y, Akinaga S, Murakata C, Yamashita Y, Yin T, Credille KM, Donoho GP, Merzoug FF, Li H, Aggarwal A, Blanchard K, Westin EH.

Mol Cancer Ther. 2015 Nov;14(11):2463-72. doi: 10.1158/1535-7163.MCT-15-0241. Epub 2015 Aug 24.

2.

Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives.

Yamamoto J, Amishiro N, Kato K, Ohta Y, Ino Y, Araki M, Tsujita T, Okamoto S, Takahashi T, Kusaka H, Akinaga S, Yamashita Y, Nakai R, Murakata C.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3961-3. doi: 10.1016/j.bmcl.2014.06.034. Epub 2014 Jun 20.

PMID:
25001485
3.

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.

Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C, Akasaka K, Ichikawa S, Ishida H, Kusaka H, Akinaga S, Murakata C, Honda S, Nitta M, Saya H, Yamashita Y.

Cancer Res. 2009 May 1;69(9):3901-9. doi: 10.1158/0008-5472.CAN-08-4373. Epub 2009 Apr 7.

4.

Glycolipids with nonreducing end alpha-mannosyl residues that have the potential to activate invariant Valpha19 NKT cells.

Shimamura M, Huang YY, Okamoto N, Watanabe Y, Murakami Y, Kinoshita T, Hirabayashi Y, Murakata C, Ito Y, Ogawa T.

FEBS J. 2007 Jun;274(11):2921-32. Epub 2007 May 4.

5.

A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.

Ishida H, Nakata T, Suzuki M, Shiotsu Y, Tanaka H, Sato N, Terasaki Y, Takebayashi M, Anazawa H, Murakata C, Li PK, Kuwabara T, Akinaga S.

Breast Cancer Res Treat. 2007 Dec;106(2):215-27. Epub 2007 Feb 1.

PMID:
17268815
6.

Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.

Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):455-60.

PMID:
14623544
7.

Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

Ikuina Y, Amishiro N, Miyata M, Narumi H, Ogawa H, Akiyama T, Shiotsu Y, Akinaga S, Murakata C.

J Med Chem. 2003 Jun 5;46(12):2534-41.

PMID:
12773056
8.

Stereospecific antitumor activity of radicicol oxime derivatives.

Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S.

Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45.

PMID:
11800023
9.

Mixed lineage kinase activity of indolocarbazole analogues.

Murakata C, Kaneko M, Gessner G, Angeles TS, Ator MA, O'Kane TM, McKenna BA, Thomas BA, Mathiasen JR, Saporito MS, Bozyczko-Coyne D, Hudkins RL.

Bioorg Med Chem Lett. 2002 Jan 21;12(2):147-50.

PMID:
11755341
10.
11.

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia.

Shiotsu Y, Yamashita K, Kanai F, Ikuina Y, Murakata C, Teramura M, Mizoguchi H, Tamaoki T, Akinaga S.

Blood. 2000 Jun 15;95(12):3771-80.

PMID:
10845909
12.

Synthesis and antitumor activity of duocarmycin derivatives: modification at C-8 position of A-ring pyrrole compounds bearing the simplified DNA-binding groups.

Amishiro N, Nagamura S, Murakata C, Okamoto A, Kobayashi E, Asada M, Gomi K, Tamaoki T, Okabe M, Yamaguchi N, Yamaguchi K, Saito H.

Bioorg Med Chem. 2000 Feb;8(2):381-91.

PMID:
10722161
13.

Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation.

Pirvola U, Xing-Qun L, Virkkala J, Saarma M, Murakata C, Camoratto AM, Walton KM, Ylikoski J.

J Neurosci. 2000 Jan 1;20(1):43-50.

14.

Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds.

Amishiro N, Okamoto A, Murakata C, Tamaoki T, Okabe M, Saito H.

J Med Chem. 1999 Jul 29;42(15):2946-60.

PMID:
10425104
15.

KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S.

Cancer Res. 1999 Jun 15;59(12):2931-8.

16.
17.

Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis.

Saporito MS, Brown ER, Carswell S, DiCamillo AM, Miller MS, Murakata C, Neff NT, Vaught JL, Haun FA.

Neuroscience. 1998 Sep;86(2):461-72.

PMID:
9881861
18.

Prodrug esters of the indolocarbazole CEP-751 (KT-6587).

Hudkins RL, Iqbal M, Park CH, Goldstein J, Herman JL, Shek E, Murakata C, Mallamo JP.

Bioorg Med Chem Lett. 1998 Jul 21;8(14):1873-6.

PMID:
9873450
19.

In vitro and in vivo effects of KT6352, a derivative of indolocarbazole compounds, on murine megakaryocytopoiesis.

Shiotsu Y, Akinaga S, Yamashita K, Murakata C, Tamaoki T, Ishida Y, Kuriya S, Teramura M, Mizoguchi H.

Exp Hematol. 1998 Dec;26(13):1195-201.

PMID:
9845374
20.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.

Clin Cancer Res. 1998 Aug;4(8):1887-98.

21.

CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo.

Glicksman MA, Chiu AY, Dionne CA, Harty M, Kaneko M, Murakata C, Oppenheim RW, Prevette D, Sengelaub DR, Vaught JL, Neff NT.

J Neurobiol. 1998 Jun 15;35(4):361-70.

PMID:
9624618
22.

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.

Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.

Int J Cancer. 1997 Aug 7;72(4):673-9.

23.

Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.

Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, Dionne CA, Angeles TS, Glicksman MA, Neff NT, Rotella DP, Kauer JC, Mallamo JP, Hudkins RL, Murakata C.

J Med Chem. 1997 Jun 6;40(12):1863-9.

PMID:
9191963
24.

KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells.

Galski H, Lazarovici P, Gottesman MM, Murakata C, Matsuda Y, Hochman J.

Eur J Cancer. 1995;31A(3):380-8.

PMID:
7786606
25.

Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives.

Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, Nakano H.

Biochemistry. 1992 Dec 8;31(48):12069-75.

PMID:
1333791
26.
28.

Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action.

Akinaga S, Ashizawa T, Gomi K, Ohno H, Morimoto M, Murakata C, Okabe M.

Cancer Chemother Pharmacol. 1992;29(4):266-72.

PMID:
1537071
29.

Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C.

Takahashi I, Kobayashi E, Nakano H, Murakata C, Saitoh H, Suzuki K, Tamaoki T.

J Pharmacol Exp Ther. 1990 Dec;255(3):1218-21.

PMID:
2262903
30.

K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.

Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata C, Sato A, Kaneko M.

Biochem Biophys Res Commun. 1987 Jan 30;142(2):436-40.

PMID:
3028414

Supplemental Content

Loading ...
Support Center